NCT05701527 - A Study of EBC-129 in Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

December 24, 2026

Study Completion Date

December 24, 2026

Conditions

Advanced Solid Tumours

Interventions

DRUG

EBC-129

EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

DRUG

Pembrolizumab

Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.

Trial Locations (5)

11217

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

77030

RECRUITING

UT MD Anderson Cancer Center, Houston

119228

RECRUITING

National University Hospital - Medical Oncology, Singapore

168583

RECRUITING

National Cancer Centre Singapore, Singapore

80045-2517

RECRUITING

University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center, Aurora